Last reviewed · How we verify
NCT03140644: SARCOLOWDOSE
SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
NA trial testing Patients with thoracic sarcoidosis in Sarcoidosis, Pulmonary in 196 participants. Completed in 15 October 2021.
15 October 2021
Quick facts
| Lead sponsor | Rennes University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 196 |
| Start date | 16 May 2017 |
| Primary completion | 15 October 2021 |
| Estimated completion | 15 October 2021 |
| Sites | 7 locations across France |
Drugs / interventions tested
- Patients with thoracic sarcoidosis
Conditions studied
- Sarcoidosis, Pulmonary — all drugs for Sarcoidosis, Pulmonary →
Sponsor
Rennes University Hospital
Who can join
18 and older, any sex, with Sarcoidosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to evaluate the diagnostic agreement between, on the one hand, ultra-low dose CT and MRI with UTE pulse sequences, and on the other hand, standard CT scan, to quantify lung parenchyma patterns in thoracic sarcoidosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03140644
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcoidosis, Pulmonary
Currently open trials in the same condition.
- NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting
- NCT06479603 — RCT of Nintedanib in Fibrotic Sarcoidosis · Phase 4 · recruiting
- NCT05746039 — Feasibility of Semaglutide in Advanced Lung Disease · Phase 1, PHASE2 · recruiting
- NCT05291468 — the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis · NA · active not recruiting
- NCT05567133 — Risk Indicators of Sarcoidosis Evolution-Unified Protocol · recruiting
Other Rennes University Hospital trials
Trials by the same sponsor.
- NCT07527949 — PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics · NA · not yet recruiting
- NCT07449832 — Sperm Epigenome in Hodgkin Lymphoma · NA · not yet recruiting
- NCT06950398 — Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers · Phase 2 · not yet recruiting
- NCT07188753 — Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-b · NA · not yet recruiting
- NCT06898099 — Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03140644 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rennes University Hospital
- Last refreshed: 17 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03140644.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing